ADMA Adma Biologics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADMA

Price (delayed)

$9.41

Market cap

$2.11B

P/E Ratio

13.07

Dividend/share

N/A

EPS

$0.72

Enterprise value

$2.17B

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 14
Relative Valuation: Rel. Valuation: 67
Relative Profitability: Rel. Profitability: 91

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk ...

Highlights
The gross profit has grown by 32% YoY and by 6% from the previous quarter
The price to earnings (P/E) is 26% lower than the last 4 quarters average of 17.7
ADMA's quick ratio is up by 36% YoY but it is down by 2.9% QoQ
The company's net income fell by 19% YoY but it rose by 2.2% QoQ
The company's debt has surged by 165% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.admabiologics.com
Peers: NVAX RGEN CVM

Key stats

What are the main financial stats of ADMA

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
-3.78%
1 week
-6.46%
1 month
4.91%
1 year
-45.29%
YTD
-48.41%
QTD
12.43%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$512.28M
Gross profit
$331.47M
Operating income
$224.48M
Net income
$168.96M
Gross margin
64.7%
Net margin
33%
Adma Biologics's operating income has increased by 44% YoY and by 4.5% QoQ
Adma Biologics's operating margin has increased by 34% YoY and by 4% QoQ
The gross profit has grown by 32% YoY and by 6% from the previous quarter
The company's net margin fell by 25% YoY

Price vs fundamentals

How does ADMA's price correlate with its fundamentals

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
ADMA P/E details
P/E
13.07
P/B
5.34
P/S
4.19
EV/EBIT
9.63
EV/EBITDA
9.31
EV/Sales
4.23
The price to earnings (P/E) is 26% lower than the last 4 quarters average of 17.7
The EPS has declined by 18% year-on-year but it has grown by 4.3% since the previous quarter
The price to book (P/B) is 29% lower than the 5-year quarterly average of 7.5 and 23% lower than the last 4 quarters average of 6.9
The equity has increased by 4.6% since the previous quarter and by 2.5% year-on-year
ADMA's price to sales (P/S) is 29% lower than its last 4 quarters average of 5.9 and 26% lower than its 5-year quarterly average of 5.7
ADMA's revenue is up by 8% year-on-year

Efficiency

How efficient is Adma Biologics business performance
The company's return on assets fell by 38% YoY and by 2.9% QoQ
ADMA's ROE is down by 36% YoY
The return on sales has grown by 35% year-on-year and by 5% since the previous quarter
The company's return on invested capital fell by 3.6% QoQ but it rose by 2.7% YoY

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 148% more than its total liabilities
Adma Biologics's total liabilities has surged by 72% YoY
ADMA's quick ratio is up by 36% YoY but it is down by 2.9% QoQ
The company's debt is 52% lower than its equity
The company's debt has surged by 165% YoY
Adma Biologics's debt to equity has surged by 153% YoY but it has decreased by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.